Patents Examined by Isaac Shomer
  • Patent number: 11413127
    Abstract: Semisolid oral dispersions for whitening teeth including hydrogen peroxide adducts in petrolatum. The hydrogen peroxide adduct can have a solubility in water of at least about 20 parts, by weight of the particles, in about 100 parts, by weight, of water. The semisolid oral dispersion and/or the petrolatum can have a cone penetration consistency value of from about 25 to about 300.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: August 16, 2022
    Assignee: The Procter & Gamble Company
    Inventors: Paul Albert Sagel, Jayanth Rajaiah, Michael David Curtis
  • Patent number: 11395799
    Abstract: The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: July 26, 2022
    Assignee: BioNTech SE
    Inventors: Heinrich Haas, Sebastian Hörner, Isaac Hernan Esparza Borquez, Thomas Michael Hiller, Ferdia Bates
  • Patent number: 11383006
    Abstract: The present disclosure is directed to a composite implant for the sustained release of a therapeutic agent from a hydrogel matrix. The hydrogel matrix may be a cross-linked bioerodible polyethylene glycol (PEG) hydrogel with a therapeutic complex dispersed within the cross-linked bioerodible PEG hydrogel. The therapeutic complex may include a therapeutic agent in association with mesoporous silica particles. The composite implant is configured to be delivered to or implanted into an eye of a subject or patient. The composite implant may be used treat ocular disease in a subject or patient. Ocular diseases may be selected from at least one of neovascular age related macular degeneration (AMD), diabetic macular edema, or macular edema following retinal vein occlusion.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: July 12, 2022
    Assignee: DOSE MEDICAL CORPORATION
    Inventors: Patrick Michael Hughes, Ina Mustafaj
  • Patent number: 11376226
    Abstract: Biodegradable polymer microparticles bearing a steroid drug and a preparation method therefor. In the method, a steroid drug and a biodegradable polyester-based polymer are dissolved in an organic solvent and sprayed into a low-temperature hydrocarbon solution to form frozen microparticles that are then immersed in a low-temperature, aqueous salt solution to deprive the microparticles of the organic solvent, thereby preparing biodegradable polymer microparticles bearing a steroid drug. The steroid drug or steroid sex hormone drug-bearing biodegradable polymer microparticles were found to have excellent biocompatibility, biodegradability, porosity, and mechanical strength and to release the steroid drug or steroid sex hormone drug for a long period of time.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: July 5, 2022
    Assignee: REGENBIOTECH, INC.
    Inventors: Jeoung Yong Kim, Won Chun Lee, Mi Yeon Kang, Hang Je Choi
  • Patent number: 11376324
    Abstract: In some aspects, the present disclosure provides vaccine compositions comprising an antigen and a diblock copolymer wherein the diblock copolymer is pH responsive. In some embodiments, these compositions activate the STING and/or the interferon receptor pathways. In some embodiments, the diblock copolymer hits a pKa from about 6 to about 7.5. Also provided herein are methods of treatment using these compositions to treat an infectious disease or cancer.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: July 5, 2022
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Jinming Gao, Zhijian Chen, Min Luo, Zhaohui Wang, Hua Wang, Haocheng Cai, Gang Huang, Yang-Xin Fu
  • Patent number: 11357736
    Abstract: The present invention relates treatments of a toxin in a subject. The toxin at least partially effects its toxicity in the subject via binding to a target cell of the subject. The present invention provides for methods, combinations and pharmaceutical compositions for decreasing or neutralizing the effect of a toxin in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, and an outer surface comprising a cellular membrane derived from a source cell. Exemplary toxins include acetylcholinesterase (AChE) inhibitors such as organophosphate poisoning.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: June 14, 2022
    Assignee: The Regents of the University of California
    Inventors: Liangfang Zhang, Zhiqing Pang, Ronnie H. Fang, Che-Ming Jack Hu
  • Patent number: 11357725
    Abstract: Metastable liposomal formulations for hydrophobic drug delivery to a tissue or tissue lumen such the bladder have been developed. These are at least one micron in diameter and formed of one or more lipids having entrapped in the lipid a hydrophobic therapeutic, prophylactic or diagnostic agent. The greater stability of these liposomes, as well as the enhanced transfer of entrapped agent into the adjacent tissue, provides for better delivery, especially of hydrophobic agents such as tacrolimus which does not penetrate tissue well. The metastable liposomal formulations can be administered locally, preferably by instillation, or topically, for example, by spraying or painting, to a tissue or tissue lumen such as the bladder in need of treatment.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: June 14, 2022
    Assignee: LIPELLA PHARMACEUTICALS INC.
    Inventors: Jonathan H. Kaufman, Michael B. Chancellor
  • Patent number: 11357724
    Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: June 14, 2022
    Assignee: CURADIGM SAS
    Inventors: Agnès Pottier, Laurent Levy, Marie-Edith Meyre, Audrey Darmon, Matthieu Germain
  • Patent number: 11344499
    Abstract: A nanoparticle comprising a keratin polypeptide and at least one lipophilic active ingredient, wherein the at least one lipophilic active ingredient is non-covalently bound to the keratin polypeptide and can be e.g. a therapeutic or diagnostic agent, a nutraceutical, a cosmetic ingredients, a dye or a cosmeceutical, the keratin polypeptide being water-soluble; optionally, the nanoparticle further comprises at least one hydrophilic active ingredient non-covalently bound to the keratin polypeptide, which can be e.g. a therapeutic or diagnostic agent, a nutraceutical, a cosmetic ingredients, a dye or a cosmeceutical.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: May 31, 2022
    Assignee: CONSIGLIO NAZIONALE DELLE RICERCHE
    Inventors: Annalisa Aluigi, Greta Varchi, Giovanna Sotgiu, Andrea Guerrini, Marco Ballestri
  • Patent number: 11337923
    Abstract: Provided are a nanoliposome-microbubble conjugate in which a drug for hair loss treatment such as finasteride, minoxidil, dutasteride, etc. is encapsulated in a nanoliposome and a composition for alleviating or treating hair loss containing the same. Since an orally administered agent such as finasteride, currently useful as a drug for hair loss treatment, causes side effects, drug delivery through scalp application is most desirable, but the drug is not delivered to hair follicle cells through scalp application alone. Since a drug for hair loss treatment useful as an external preparation for skin causes various side effects, the concentration thereof that is used needs to be further lowered. The above nanoliposome-microbubble conjugate is capable of increasing the delivery efficiency of a drug for hair loss treatment at a low concentration, and is thus very effective at treating androgenic alopecia.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: May 24, 2022
    Assignee: MOOGENE MEDI CO., LTD.
    Inventor: Kyeong Nam Yu
  • Patent number: 11337924
    Abstract: The invention relates to a novel drug delivery vehicle. Various embodiments of the invention provide a hybrid polymerized liposomal nanoparticle comprising both polymerizable lipids and non-polymerizable lipids. Therapeutic agents can be loaded into the polymerized liposomal nanoparticle and targeting agents can be conjugated to the surface of the polymerized liposomal nanoparticle. Also described in the invention are methods, compositions and kits that utilize the hybrid polymerized liposomal nanoparticle to treat disease conditions such as various cancers.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: May 24, 2022
    Assignees: Children's Hospital Los Angeles, Nanovalent Pharmaceuticals, Inc.
    Inventors: Jon O. Nagy, Tim Triche, Hyung-Gyoo Kang
  • Patent number: 11324678
    Abstract: This invention provides core shell silica particles, wherein each core shell silica particle comprises a silica core, and a surface of the silica core etched with group I metal silicate. These core shell silica particles have high surface charge density and anti-bacterial activity. Also provided are compositions comprising core shell silica particles, process of making the core shell silica particles and methods of reducing or inhibiting bacterial activity by administering the core shell silica particles or compositions thereof.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: May 10, 2022
    Assignee: Colgate-Palmolive Company
    Inventors: Guisheng Pan, Suman Chopra
  • Patent number: 11324828
    Abstract: Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel for controlled release of a therapeutic agent.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: May 10, 2022
    Assignee: Incept, LLC
    Inventors: Amarpreet S. Sawhney, William H. Ransone, II
  • Patent number: 11318097
    Abstract: Provided herein are liposomal vesicles comprising at least a first lipid bilayer and a second lipid bilayer, and a plurality of crosslinkages between the first lipid bilayer and the second lipid bilayer, wherein the plurality of crosslinkages comprise boronic ester or thioketal bonds. Also provided are pharmaceutical compositions comprising the liposomal vesicles described herein and a pharmaceutically acceptable excipient. Also provided are methods of making and using the liposomal vesicles. Thus, a method of treating a subject with a disease comprising administering to the subject a pharmaceutical composition comprising the liposomal vesicles is described herein. Methods of making multilamellar liposomal vesicles responsive to reactive oxygen species are also provided.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: May 3, 2022
    Assignee: Verily Life Sciences LLC
    Inventors: Zhan Wang, Stephen Morton
  • Patent number: 11311493
    Abstract: This invention relates to methods of preparing nanotherapeutic compounds and compositions comprising nanotherapeutic compounds. The nanotherapeutic compounds prepared according to the methods provided herein are useful for the treatment of disease, for example, cancer, in a subject in need thereof.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: April 26, 2022
    Assignee: MAA Laboratories, Inc.
    Inventor: Anjani Kumar Jha
  • Patent number: 11304901
    Abstract: The present invention is directed to a liposomal formulation having a lipid ingredient encapsulating fluticasone furoate, and a method for preparing the liposomal formulation. The liposome formulation comprises a lipid and a sterol. The method of preparing the liposomes comprises the steps of (1) mixing fluticasone furoate with lipid ingredients comprising a lipid and a sterol, (2) injecting the mixture into normal saline solution, and (3) ultrafiltering and concentrating the resulting solution. This preparation method can produce a liposome formulation having desirable properties and compositions, for example, the ratio of the lipid ingredient, the drug to lipid ratio, and the pH value, which is suitable for nebulization inhalation.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: April 19, 2022
    Assignee: ANOVENT PHARMACEUTICAL (U.S.), LLC
    Inventors: Cai Gu Huang, Hailong Zhang, Abid Hussain
  • Patent number: 11304902
    Abstract: The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: April 19, 2022
    Assignee: CURADIGM SAS
    Inventors: Agnes Pottier, Matthieu Germain, Laurence Poul, Marion Paolini, Marie-Edith Meyre
  • Patent number: 11298375
    Abstract: The present invention provides the methods and composition useful as a contraceptive by preventing motile sperm from reaching a mature ovum, thereby blocking fertilization and preventing pregnancy. The contraceptive is comprised of halogen functionalized fullerene nanoparticles (halo fullerenes) and chemotactic stimulants that act synergistically to divert, incapacitate and ultimately rupture spermatozoa to avert fertilization. When applied vaginally prior to coitus, the suspension is activated by exposure to spermatozoa upon insemination. Notably, non-spermatozoa cells are unaffected by the pH-neutral suspension; however, closer to the same scale, microbes are susceptible to its inherent biocidal properties. Following application and coitus, the contraceptive evacuates naturally, along with seminal and vaginal fluids thereafter.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: April 12, 2022
    Inventors: Terry Earl Brady, Anthony Lee Dellinger, Melinda K. M. Goddard, Kristen Dellinger
  • Patent number: 11285088
    Abstract: Silica particles having a d50 median particle size of at least 6 ?m, a ratio of (d90?d10)/d50 from 1.1 to 2.4, a RDA at 20 wt. % loading from 40 to 200, and a sphericity factor (S80) of at least 0.9, are disclosed, as well as methods for making these silica particles, and dentifrice compositions containing the silica particles.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: March 29, 2022
    Assignee: Evonik Operations GmbH
    Inventors: William J. Hagar, Terry W. Nassivera, Karl W. Gallis
  • Patent number: 11285111
    Abstract: A particle-producing method is provided including the processes of: discharging a liquid from discharge holes provided on a liquid-storing unit storing the liquid to make the liquid into droplets, the liquid containing a physiologically active substance and a polymer; and solidifying the droplets into a particle.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: March 29, 2022
    Assignee: RICOH COMPANY, LTD.
    Inventors: Naoki Shiraishi, Tatsuru Moritani, Tadahiko Morinaga